{
    "clinical_study": {
        "@rank": "136037", 
        "arm_group": [
            {
                "arm_group_label": "50 mg GLPG0974 or placebo", 
                "arm_group_type": "Other", 
                "description": "50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days"
            }, 
            {
                "arm_group_label": "100 mg GLPG0974 or placebo", 
                "arm_group_type": "Other", 
                "description": "100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days"
            }, 
            {
                "arm_group_label": "200 mg GLPG0974 or placebo", 
                "arm_group_type": "Other", 
                "description": "200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days"
            }, 
            {
                "arm_group_label": "400 mg GLPG0974 or placebo", 
                "arm_group_type": "Other", 
                "description": "400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability after multiple\n      ascending oral doses of GLPG0974 given to healthy male subjects for 14 days, compared to\n      placebo.\n\n      Furthermore, during the course of the study, the amount of GLPG0974 present in the blood and\n      urine (pharmacokinetics) as well as the effects of GLPG0974 on mechanism of action-related\n      parameters in the blood and stool samples (pharmacodynamics) will be characterized compared\n      to placebo.\n\n      Also, the effect of the compound on glucose tolerance will be explored as well as the\n      potential of cytochrome P450 (CYP)3A4 induction by repeated dosing with GLPG0974."
        }, 
        "brief_title": "Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male, age 18-50 years\n\n          -  BMI between 18-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721980", 
            "org_study_id": "GLPG0974-CL-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "50 mg GLPG0974 or placebo", 
                    "100 mg GLPG0974 or placebo", 
                    "200 mg GLPG0974 or placebo", 
                    "400 mg GLPG0974 or placebo"
                ], 
                "intervention_name": "GLPG0974", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "50 mg GLPG0974 or placebo", 
                    "100 mg GLPG0974 or placebo", 
                    "200 mg GLPG0974 or placebo", 
                    "400 mg GLPG0974 or placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }, 
                "name": "SGS LSS Clinical Pharmacology Unit Antwerp"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Double-blind, Randomized, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0974 in Healthy Male Subjects", 
        "other_outcome": [
            {
                "description": "Potential of CYP3A4 induction by repeated dosing with GLPG0974 will be assessed by means of the ratio of 6b-hydroxycortisol/cortisol in urine", 
                "measure": "Ratio of 6b-hydroxycortisol/cortisol in urine", 
                "safety_issue": "No", 
                "time_frame": "Predose and postdose on Day 1 and Day 13 for 24h"
            }, 
            {
                "description": "Concentrations of faecal calprotectin will be measured as a pharmacodynamic marker in a single stool sample predose and postdose", 
                "measure": "Levels of faecal calprotectin in stool", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dosing and postdose (between Day 12 and 15)"
            }, 
            {
                "description": "Oral glucose tolerance test by means of measuring concentrations of glucose and insulin after glucose loading, once predosing and once postdosing of GLPG0974", 
                "measure": "Glucose and insulin concentrations after glucose loading", 
                "safety_issue": "Yes", 
                "time_frame": "Day -1 (predose) and Day 14 (postdose)"
            }
        ], 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability of GLPG0974 in comparison with placebo after a single oral dose in healthy subjects in terms of adverse events, physical examinations, vital signs, ECG and lab assessments", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Between screening and 7-10 days after the last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the amount of GLPG0974 in plasma and urine over time - pharmacokinetics (PK) - after multiple oral doses in healthy subjects", 
                "measure": "The amount of GLPG0974 in plasma and urine over time after multiple oral dose", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 predose and Day 14"
            }, 
            {
                "description": "To characterize the pharmacodynamics (PD) of GLPG0974 by means of inhibition of expression of CD11b on neutrophils after multiple oral doses in healthy subjects", 
                "measure": "Inhibition of CD11b on neutrophils in blood after multiple oral doses of GLPG0974", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 13, predose until 24h post dose"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}